GENFIT (GNFT)
(Delayed Data from NSDQ)
$4.09 USD
-0.67 (-14.08%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $4.33 +0.24 (5.87%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Brokerage Reports
GENFIT S.A. Unsponsored ADR [GNFT]
Reports for Purchase
Showing records 21 - 40 ( 115 total )
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
We Expect OCEANE Buybacks and Amendments to Improve Financial Flexibility; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
1H20 Recap: With No Meaningful Near-Term Catalysts, We Remain on the Sidelines
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
LabCorp Signs Agreement to Develop and Market NIS4 Non-Invasive NASH Diagnostic Test; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Dosing Underway for Phase 3 ELATIVE Study in PBC; Major Announcement on Sept 30
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Validation of NIS4 NASH Diagnostic Published in The Lancet Ahead of Expected Partnership in 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Realigning Its Focus on Elafibranor for PBC and NIS4 NASH Diagnostic; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare- Three Must Dial-In Calls Next Week:
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Three Must Dial-In Calls Next Week: NASH, Omega-3s, and COVID-19 - MS
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
RESOLVE-IT Failure Leaves PBC as Sole Value Driver; Downgrade to Neutral, PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
NASH: Impact of Semaglutide GLP-1 NASH Data on NASH Stocks
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
FY19 Recap; Top-line Pivotal NASH Data Next Month; PT to $46 on Timeline Delay
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
4Q19 - A Deep Dive as We Head into RESOLVE-IT Data End of May 2020
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y